Shenzhen Bioeasy Biotechnology Co., Ltd. (SHE:300942)
China · Delayed Price · Currency is CNY 6.55
+0.18 (2.83%)
Aug 4, 2026, 3:04 PM CST
SHE:300942 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 2,653 | 3,812 | 3,435 | 4,686 | 6,871 | 11,569 | |
Market Cap Growth | -41.18% | 10.95% | -26.69% | -31.80% | -40.61% | - |
Enterprise Value | 2,521 | 3,664 | 3,264 | 4,428 | 6,587 | 10,922 |
Last Close Price | 6.55 | 9.38 | 8.52 | 11.63 | 17.02 | 28.34 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 388.48 | 277.35 | 200.71 | - | 82.81 | 48.92 |
PS Ratio | 9.77 | 14.48 | 15.32 | 18.44 | 10.00 | 19.36 |
PB Ratio | 2.95 | 4.20 | 3.95 | 5.52 | 7.12 | 12.22 |
P/TBV Ratio | 3.10 | 4.40 | 4.14 | 5.80 | 7.45 | 12.82 |
P/FCF Ratio | - | 181.75 | - | - | - | 65.76 |
P/OCF Ratio | 47.58 | 57.00 | 100.28 | - | 45.04 | 45.29 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 9.28 | 13.92 | 14.56 | 17.43 | 9.59 | 18.28 |
EV/EBITDA Ratio | 53.05 | 81.24 | 108.64 | - | 78.20 | 42.48 |
EV/EBIT Ratio | 181.17 | 236.43 | 198.38 | - | 90.53 | 44.02 |
EV/FCF Ratio | - | 174.69 | - | - | - | 62.09 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.51 | 0.49 | 0.54 | 0.43 | 0.12 | 0.04 |
Debt / EBITDA Ratio | 9.71 | 9.92 | 12.40 | - | 1.16 | 0.15 |
Debt / FCF Ratio | - | 21.34 | - | - | - | 0.23 |
Net Debt / Equity Ratio | -0.15 | -0.20 | -0.15 | -0.28 | -0.32 | -0.68 |
Net Debt / EBITDA Ratio | -2.91 | -4.00 | -4.27 | 2.39 | -3.68 | -2.49 |
Net Debt / FCF Ratio | 17.43 | -8.61 | 0.92 | 1.42 | 12.76 | -3.64 |
Asset Turnover | 0.19 | 0.18 | 0.16 | 0.19 | 0.56 | 0.66 |
Inventory Turnover | 1.92 | 2.04 | 1.90 | 2.39 | 3.55 | 2.21 |
Quick Ratio | 6.46 | 4.61 | 4.56 | 4.98 | 2.65 | 5.02 |
Current Ratio | 7.29 | 5.09 | 4.95 | 5.39 | 3.38 | 5.73 |
Return on Equity (ROE) | 1.04% | 1.74% | 1.93% | -20.40% | 8.65% | 31.62% |
Return on Assets (ROA) | 0.59% | 0.65% | 0.73% | -5.42% | 3.74% | 17.18% |
Return on Invested Capital (ROIC) | 1.87% | 2.11% | 2.05% | -18.06% | 13.21% | 92.13% |
Return on Capital Employed (ROCE) | 1.00% | 1.10% | 1.30% | -9.40% | 6.70% | 24.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.26% | 0.36% | 0.50% | -3.95% | 1.21% | 2.04% |
FCF Yield | -0.30% | 0.55% | -4.07% | -3.54% | -0.35% | 1.52% |
Dividend Yield | 0.39% | 0.26% | 0.21% | - | 0.13% | 0.88% |
Payout Ratio | 208.15% | 100.83% | 31.18% | - | 121.32% | 7.63% |
Buyback Yield / Dilution | -7.11% | -7.06% | -6.45% | -1.75% | -0.23% | -8.42% |
Total Shareholder Return | -6.71% | -6.79% | -6.25% | -1.75% | -0.10% | -7.54% |